Skip to main content

Table 9 Group comparison (mean ± SD) in molecular biomarkers between patients on lovastatin vs. placebo

From: Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome

BiomarkerLovastatin+PILIPlacebo+PILIBetween-group comparison
BaselinePostWithin-group: baseline vs. postBaselinePostWithin-group: baseline vs. postBaselinePostPost, adjusted for baseline
MMP6.36 ± 2.846.25 ± 2.48t(11) = − 0.09 (0.9313)6.69 ± 3.657.20 ± 4.10t(12) = − 0.99 (0.3407)F(1, 24) = 0.01 (0.9383)F(1, 23) = 0.18 (0.675)F(1, 22) = 0.48 (0.4935)
ERK0.48 ± 0.260.58 ± 0.32t(11) = − 0.62 (0.5502)0.50 ± 0.220.84 ± 0.98t(12) = − 1.16 (0.2676)F(1, 23) = 0.16 (0.6911)F(1, 23) = 0.57 (0.4599)F(1, 22) = 0.64 (0.4332)
S6K0.11 ± 0.100.11 ± 0.11t (11) = 1.11 (0.2891)0.14 ± 0.260.08 ± 0.04t(11) = 0.66 (0.5203)F(1, 23) = 0.08 (0.7772)F(1, 22) = 0.07 (0.7878)F(1, 21) = 0.09 (0.772)